> **Galenica demonstrates pleasing growth and improves EBIT guidance - Galenica.com**

> Galenica Group sales grew by 5.0% to CHF 1,995.4 million in the first half of 2025.Adjusted EBIT<sup>1</sup> increased by 10.9% to CHF 109.

- Language: en
- Last Modified: 2026-11-20
- Source: <https://www.galenica.com/en/storyhub/eqs/01f97419-ead7-418e-8c18-4521046a6389.php>
- Alternate (fr): <https://www.galenica.com/fr/storyhub/eqs/01f97419-ead7-418e-8c18-4521046a6389.php>
- Alternate (de): <https://www.galenica.com/de/storyhub/eqs/01f97419-ead7-418e-8c18-4521046a6389.php>
- Search: <https://www.galenica.com/en/search/index.php?searchTerm={search_term_string}>

---

Ad hoc announcement pursuant to Art. 53 LR  2025/08/07

# Galenica demonstrates pleasing growth and improves EBIT guidance

- Galenica Group sales grew by 5.0% to CHF 1,995.4 million in the first half of 2025.
- Adjusted EBIT1 increased by 10.9% to CHF 109.9 million – supported by positive one-time effects of CHF 5.4 million.
- Galenica is therefore raising its EBIT guidance and now expects growth between 7% and 9% (previously growth between 4% and 6%).
- Guidance for 2025 sales growth remains unchanged at 3% to 5%, the dividend is expected to remain at least at the previous year’s level.

Galenica recorded pleasing growth in a positive market environment in the first half of 2025. Both the “Products & Care” segment (+4.6%) and the “Logistics & IT” segment (+5.5%) contributed to the increase in sales of 5.0% to CHF 1,995.4 million. As a result, Galenica Group sales grew slightly stronger than the pharmaceutical market (+4.8%2) and the consumer healthcare market (+0.6%3).

### Strong sales growth in prescription drugs

Following an increase of 4.7% by the end of April 2025, Galenica Group sales increased further in May and June 2025. Growth in the first half of the year was driven by strong demand for prescription drugs, including GLP-1-based4 weight loss products, as well as drugs associated with the heavy flu season early in the year. The good result was achieved despite one less day of sales compared to the same period in the previous year.

Reported EBIT increased by 6.2% to CHF 108.8 million, while adjusted EBIT1 increased by 10.9% to CHF 109.9 million. In the first half of 2025, EBIT was supported by the pleasing sales growth as well as by positive one-off effects in the amount of CHF 5.4 million. Without these effects, adjusted EBIT1 would have increased by 5.4%. The reason for this is that fines in two competition proceedings were significantly lower than originally expected, positively impacting the “Logistics & IT” segment.

### Improved EBIT guidance for the second half of the year

Galenica confirms its 2025 outlook for consolidated net sales with growth of between 3% and 5% and the dividend at least at the same level as the previous year. Due to the strong growth in the first half of the year and positive one-time effects of CHF 5.4 million, Galenica now expects an EBIT1 increase of between 7% and 9%. Prior to this, growth of between 4% and 6% had been expected.

In early July 2025, Galenica announced the acquisition of the diagnostics service provider Labor Team. As the closing date of the transaction has not yet been determined, the Labor Team Group is not yet included in the 2025 guidance .

### Key figures of the Galenica Group in the first half of 2025

| (in million CHF) | 1st half of 2025 | 1st half of 2024 | Change |
| --- | --- | --- | --- |
| Net sales |  |  |  |
| Products & Care segment | 867.3 | 829.3 | +4.6% |
| Retail (B2C) | 731.1 | 695.4 | +5.1% |
| Local Pharmacies | 693.1 | 657.6 | +5.4% |
| Pharmacies at Home | 38.1 | 37.9 | +0.3% |
| Professionals (B2B) | 140.9 | 138.4 | +1.8% |
| Products & Brands | 97.8 | 97.0 | +0.9% |
| Services for Professionals | 43.1 | 41.4 | +4.0% |
| Logistics & IT segment | 1,649.7 | 1,563.3 | +5.5% |
| Wholesale | 1,579.6 | 1,496.5 | +5.6% |
| Logistics & IT Services | 83.0 | 77.7 | +6.9% |
| Corporate and eliminations | -521.7 | -492.6 |  |
| Galenica Group | 1,995.4 | 1,900.0 | +5.0% |
| EBIT adjusted1 |  |  |  |
| Products & Care segment | 79.5 | 75.9 | +4.6% |
| Logistics & IT segment | 32.0 | 25.4 | +25.8% |
| Corporate and eliminations | -1.6 | -2.2 |  |
| Galenica Group | 109.9 | 99.1 | +10.9% |
| Net profit from ongoing business activities adjusted1 | 90.7 | 77.7 | +16.8% |

1) Excluding the effects of IFRS 16 and IAS 19 (details of the adjusted key figures in the [half year report 2025](https://report.galenica.com/hyr25/))

2) IQVIA, Pharmaceutical Market Switzerland, YTD June 2025.

3) IQVIA, Consumer Health Market Switzerland, YTD June 2025.

4) GLP-1 stands for glucagon-like peptide 1, a hormone produced in the intestine and which plays an important role in regulating blood sugar levels.

### Detailed information in the half year report 2025:

- Management report of the Galenica Group
- Management report for the Products & Care segment
- Management report for the Logistics & IT segment
- Key figures

| Conference call at 2 p.m.

Galenica will host a Zoom Conference Call on the results for the first half of 2025 today, Thursday, 7 August 2025, at 2 p.m. (CEST). You can follow the Zoom conference via this link: Zoom conference (meeting: 880 3349 4358, code: 2466)

The conference will be held in German with simultaneous English interpreting. The presentation will be available on the website from around 12 noon (CEST) on 7 August 2025. A recording of the conference call will then be made available on the website. |
| --- |

[Galenica Group half-year results 2025](https://eqs-cockpit.com/c/fncls.ssp?u=5b3b995e86a23a07e503cedb0984469f&inline_display=1)

Share post:

[back](https://www.galenica.com/de/news/entries/2024-10-22-partnerschaft-stapferhaus.php)

## Media inquiries & contact

Do you have questions about Galenica?
Get in touch with us.

[Media inquiries & contact](https://www.galenica.com/en/medien-news/medienkontakte.php)

## You might also be interested in this

Press releases

2026/11/18

#### Verfora acquires majority stake in distribution partner Qpharma

With Qpharma, Verfora is gaining an established Polish pharmaceutical distributor with a strong distribution platform in Central and Eastern Europe.

[Verfora acquires majority stake in distribution partner Qpharma](https://www.galenica.com/en/storyhub/eqs/86792312-b676-44cf-85a8-3274a5ad078e.php)

Press releases

2026/10/26

#### Galenica successfully places a bond of over CHF 200 million

Today, Galenica successfully placed a fixed rate bond of over CHF 200 million. The bond has a term of 4 years and an annual coupon of 1.2775%.

[Galenica successfully places a bond of over CHF 200 million](https://www.galenica.com/en/storyhub/eqs/216bfdff-51da-47a5-b9fd-a0fb4222acf2.php)

Ad hoc announcements

2026/10/22

#### Galenica continues growth trajectory and confirms outlook for 2026

Galenica increases sales by 5.7% to CHF 3,172.0 million in the first nine months of 2026. The pharmacy business and home care are key contributors to growth.

[Galenica continues growth trajectory and confirms outlook for 2026](https://www.galenica.com/en/storyhub/eqs/75d2d9ff-4b40-4a24-8f9a-71d7d8e85670.php)

2026/09/17

#### Five football pitches full of medication – and one system for emergencies

Millions of packs of medicines are stored in Burgdorf. Some of them are intended for the moment when the market can no longer guarantee supply. How this compulsory stock works and is drawn upon, why it is far from being a dusty emergency reserve, and what role the Galenica network company Alloga plays in supplying Switzerland.

[Five football pitches full of medication – and one system for emergencies](https://www.galenica.com/en/news/entries/20260915-6827872869-news.php)

2026/09/01

#### A new gem joins the network: Galenica acquires Bären Apotheke am Zytglogge

The long-established Bären Apotheke am Zytglogge has been part of Bern’s cityscape for generations. Since 1 September 2026, it has been part of the Galenica network and continues to operate under the name “Bären Vita Zytglogge” with a new concept. This preserves a piece of Bern’s history while opening up new prospects for its future.

[A new gem joins the network: Galenica acquires Bären Apotheke am Zytglogge](https://www.galenica.com/en/news/entries/20260831-1530729059-news.php)

2026/08/31

#### Creating New Spaces in Harmony with Our Culture

The world of work is constantly evolving, and Galenica is evolving with it. As part of our transformation, we are actively shaping the future. This is reflected not only in the way we collaborate, but also in the environments in which we work.

[Creating New Spaces in Harmony with Our Culture](https://www.galenica.com/en/news/entries/20260828-4185621035-news.php)

Ad hoc announcements

2026/08/06

#### Galenica maintains its track record of consistent growth

Galenica increases sales by 7.1% to CHF 2,136.5 million in the first half of 2026. Adjusted<sup>1</sup> EBIT increases by 7.1% to CHF 117.7 million.

[Galenica maintains its track record of consistent growth](https://www.galenica.com/en/storyhub/eqs/56b03300-1d96-40ad-8ba5-2aa0e5bb109b.php)

2026/06/30

#### Change in the Executive Committee of Labor Team

Alain M. Cahen will step down as CEO of Labor Team at the end of June 2026 and will also leave the Executive Committee. COO Thomas Brinkmann will take over on an interim basis.

[Change in the Executive Committee of Labor Team](https://www.galenica.com/en/news/entries/20260630-1601920926-news.php)

Video

2026/06/18

#### Coordinated basic care: From pilot projects to system solutions

Collaboration between different healthcare providers is already being tested in numerous pilot projects. One recent example is the Baselland supply model, which also involves participation from pharmacies in the Galenica network. The task going forward is to develop these approaches systematically and translate them into sustainable, broad-based system solutions. Daniele Madonna, Chief Pharmacies Category Management & Health Services, called for this step at this year’s Healthcare Professionals Initiative on 5 June 2026.

[Coordinated basic care: From pilot projects to system solutions](https://www.galenica.com/en/news/entries/20260617-4349880772-news.php)

Video

2026/06/01

#### Sun Store Renens: First pharmacy in Western Switzerland to introduce the new concept

With the redesigned Sun Store pharmacy in Renens (VD), the first pharmacy in Western Switzerland is opening with a completely new concept. It places a strong focus on personalised advice, healthcare services and the overall customer experience. The aim is to further improve people’s access to low-threshold primary care services.

[Sun Store Renens: First pharmacy in Western Switzerland to introduce the new concept](https://www.galenica.com/en/news/entries/20260428-7147085906-news.php)